3,120 Shares in Eli Lilly and Company $LLY Purchased by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,120 shares of the company’s stock, valued at approximately $2,381,000.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Sequoia Financial Advisors LLC grew its position in Eli Lilly and Company by 19.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after acquiring an additional 22,410 shares in the last quarter. Schnieders Capital Management LLC. grew its position in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Finally, Jupiter Asset Management Ltd. increased its stake in Eli Lilly and Company by 1.9% during the second quarter. Jupiter Asset Management Ltd. now owns 21,449 shares of the company’s stock worth $16,720,000 after purchasing an additional 390 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Argus upped their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Up 1.3%

NYSE LLY traded up $12.26 on Friday, hitting $989.51. 614,389 shares of the stock were exchanged, compared to its average volume of 3,156,544. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a 50-day moving average price of $1,039.17 and a 200-day moving average price of $947.29. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a market cap of $934.91 billion, a PE ratio of 43.15, a PEG ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue was up 42.6% on a year-over-year basis. During the same period last year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access expansion for tirzepatide drugs (Zepbound, Mounjaro) broadens insured demand and reduces out-of-pocket barriers, supporting near-term volume growth. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Large international capacity investments — most notably a $3B China manufacturing commitment plus separate Korea and Japan investments — reduce supply risk, support local pricing flexibility, and position Lilly to capture rapid GLP‑1 market growth in APAC. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Pipeline and commercial initiatives remain growth drivers: the company is filing/launching oral GLP‑1 orforglipron (mid‑2026 target) and promoting Employer Connect / LillyDirect to expand employer coverage — potential to materially increase addressable market and volumes if uptake continues. Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
• Neutral Sentiment: Analyst and market narrative remains bullish on long‑term GLP‑1 dominance (strong buy calls, elevated price targets) even as management guides for slower but still robust EPS growth — supports long‑term thesis but keeps expectations high. Eli Lilly: The Weight-Loss Craze Isn’t Over
• Negative Sentiment: Safety/regulatory overhang — Lilly flagged a concerning unknown impurity in compounded (non‑commercial) tirzepatide mixed with vitamin B12; that warning could prompt tighter scrutiny of compounding practices and consumer caution, and generate negative headlines or enforcement actions. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Near-term market psychology and trading momentum concerns: some commentators warn the GLP‑1 euphoria and LLY’s price action have weakened since late 2025, raising risk of multiple compression or short‑term pullbacks despite solid fundamentals. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.